06/02/23 6:45 AMNasdaq : BNTX clinical trialBioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO BNT316/ONC-392 is a next-generation anti-CTLA-4 monoclonal antibody candidate jointly developed by BioNTech and OncoC4 as monotherapy or combination therapy in a range of solid tumor indications, including non-small cell lung cancer (NSCLC) Interim data of BNT316/ONC-392 from the ongoing Phase 1/2RHEA-AIneutral
05/08/23 6:45 AMNasdaq : BNTX earningsBioNTech Announces First Quarter 2023 Financial Results and Corporate UpdateCOVID-19 vaccine franchise focused on vaccine adaptation readiness ahead of the fall season and advancing next generation vaccine candidates and combinations BioNTech and partner OncoC4 plan to start a Phase 3 clinical trial evaluating anti-CTLA-4 antibody BNT316 (ONC-392) as monotherapy in NSCLCRHEA-AIneutral
04/24/23 6:45 AMNasdaq : BNTX conferencesearningsBioNTech to Report First Quarter 2023 Financial Results and Operational Update on May 8, 2023MAINZ, Germany , April 24, 2023 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2023 on Monday, May 8 th, 2023. BioNTech invites investors and the general public to join a conference call and webcast withRHEA-AIneutral
04/03/23 6:45 AMNasdaq : BNTX partnershipBioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid TumorsBioNTech receives exclusive licenses from DualityBio for two investigational antibody-drug conjugate assets (DB-1303 and DB-1311) directed against targets expressed in a broad range of human cancers Collaboration will add a new class of precision medicine therapeutics to BioNTech’s clinical-stageRHEA-AIpositive
03/28/23 6:45 AMNasdaq : BNTX buybackBioNTech Announces New ADS Repurchase ProgramBioNTech SE (Nasdaq: BNTX, “BioNTech” or the “Company”) today announced that it has entered into a new share repurchase program (the “Program”), pursuant to which the Company may purchase American Depositary Shares, each representing one ordinaryRHEA-AIneutral
03/27/23 6:45 AMNasdaq : BNTX earningsBioNTech Announces Fourth Quarter and Full Year 2022 Financial Results and Corporate UpdateExpanded and advanced oncology pipeline to 20 programs in 24 ongoing clinical trials including five ongoing randomized Phase 2 clinical trials; multiple trials with registrational potential expected to be initiated in 2023 and 2024 Announced licensing agreement with OncoC4 to complement theRHEA-AIpositive
03/20/23 7:45 AMNasdaq : BNTX BioNTech and OncoC4 Announce Strategic Collaboration to Co-Develop and Commercialize Novel Checkpoint Antibody in Multiple Solid Tumor IndicationsBioNTech to receive exclusive worldwide license from OncoC4 to develop and commercialize its anti-CTLA-4 monoclonal antibody candidate, ONC-392 BioNTech and OncoC4 will co-develop ONC-392 as monotherapy or in combination with anti-PD1 in various solid tumor indications, with a randomized Phase 3RHEA-AIvery positive
03/13/23 7:45 AMNasdaq : BNTX conferencesearningsBioNTech to Report Full Year and Fourth Quarter 2022 Financial Results and Operational Update on March 27, 2023MAINZ, Germany , March 13, 2023 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the full year and fourth quarter 2022 on Monday, March 27 th, 2023. BioNTech invites investors and the general public to join a conference call andRHEA-AIneutral
03/01/23 8:00 AMNasdaq : BNTX BioNTech Announces Establishment of Interdisciplinary mRNA Excellence Center to Conduct Research Jointly with Scientists from Weizmann Institute of Science in IsraelJERUSALEM, Israel, March 1, 2023 – BioNTech SE (Nasdaq: BNTX, “BioNTech”, “the Company”) announced that the Company and the Weizmann Institute of Science (“Weizmann Institute”) signed a Memorandum of Understanding (MoU). As part of this MoU, scientists from a variety of disciplines from BioNTechRHEA-AIpositive
02/02/23 6:45 AMNasdaq : BNTX BioNTech Strengthens Manufacturing Capabilities with First In-House Plasmid DNA Manufacturing FacilityPlasmids are an important starting material for the manufacturing of mRNA- and cell-based drugs The new plasmid manufacturing facility aims to increase BioNTech’s autonomy and flexibility in manufacturing an important starting material for its oncology and COVID-19 vaccine pipeline The investmentRHEA-AIvery positive